1205 completed, 315 terminated, 229 recruiting, 184 unknown. 1019 Phase 2, 615 Phase 1, 232 Phase 3, 157 Not applicable, 45 Phase 4.
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rusfertide in Adults With Polycythemia Vera in China Rusfertide - Polycythemia Vera | Phase 2 | Not yet recruiting | Takeda | 24 | 2027-03-01 | 2026-08-28 |
| WELL-MPN: A Digital Lifestyle App for Patients With MPNs WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs) | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 75 | 2027-01-01 | 2026-09-29 |
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera No Intervention - Polycythemia Vera | Not yet recruiting | Takeda | 90 | 2026-12-01 | 2026-10-09 | |
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm | Phase 1 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-12-01 | 2026-10-21 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | University of Arizona | 180 | 2026-11-30 | 2026-10-22 |
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis bomedemstat - Myelofibrosis | Phase 2 | Not yet recruiting | United Lincolnshire Hospitals NHS Trust | 40 | 2026-11-01 | 2026-02-20 |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
| A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera AG-236, Placebo - Polycythemia Vera | Phase 2 / Phase 3 | Not yet recruiting | Agios Pharmaceuticals, Inc. | 245 | 2026-11-01 | 2026-10-13 |
| Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera Epetraborole, Placebo - Polycythemia Vera (SNOMED CT: 109992005) | Phase 2 | Not yet recruiting | AN2 Therapeutics, Inc | 75 | 2026-11-01 | 2026-10-23 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-11-01 | 2026-10-27 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-11-01 | 2026-10-27 |
Showing 20 of 2233. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (876) · Leukemia, Myeloid, Acute (821) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (649) · Myelodysplastic Syndromes (623) · Leukemia (618) · Primary Myelofibrosis (618) · Leukemia, Myeloid, Chronic-Phase (438) · Leukemia, Lymphocytic, Chronic, B-Cell (411) · Lymphoma, Non-Hodgkin (385) · Multiple Myeloma (358) · Hodgkin Disease (357) · Blast Crisis (356) · Congenital Abnormalities (327) · Leukemia, Myeloid, Accelerated Phase (318)
Hemic and Lymphatic Diseases (2232) · Bone Marrow Diseases (2200) · Hematologic Diseases (2176) · Neoplasms (1775) · Neoplasms by Histologic Type (1666) · Leukemia, Myeloid (1566) · Pathological Conditions, Signs and Symptoms (1452) · Pathologic Processes (1440) · Disease Attributes (1424) · Chronic Disease (1416) · Leukemia (1032) · Immune System Diseases (820) · Immunoproliferative Disorders (785) · Lymphatic Diseases (779)
Cyclophosphamide (227) · fludarabine phosphate (197) · Imatinib Mesylate (172) · Cytarabine (155) · Busulfan (151) · Peripheral Blood Stem Cell Transplantation (150) · ruxolitinib (137) · Mycophenolic Acid (134) · Whole-Body Irradiation (127) · Tacrolimus (125) · Cyclosporine (110) · fludarabine (110) · Filgrastim (109) · nilotinib (106) · Methotrexate (93)
M.D. Anderson Cancer Center (128) · Novartis Pharmaceuticals (120) · National Cancer Institute (NCI) (112) · Fred Hutchinson Cancer Center (103) · Memorial Sloan Kettering Cancer Center (44) · Bristol-Myers Squibb (38) · Masonic Cancer Center, University of Minnesota (37) · City of Hope Medical Center (35) · Incyte Corporation (34) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (30) · Case Comprehensive Cancer Center (29) · Gruppo Italiano Malattie EMatologiche dell'Adulto (27) · National Heart, Lung, and Blood Institute (NHLBI) (27) · Roswell Park Cancer Institute (26) · H. Lee Moffitt Cancer Center and Research Institute (18)
United States (1437) · Italy (270) · France (268) · Germany (220) · Canada (188) · United Kingdom (167) · Spain (146) · Australia (120) · China (115) · South Korea (114) · Belgium (107) · Poland (92) · Netherlands (91) · Israel (86) · Austria (78)
Jorge Cortes, MD (19) · John Mascarenhas, MD (16) · Brenda Sandmaier (15) · Ronald Hoffman, MD (12) · Jorge E Cortes, MD (8) · B. Douglas Smith, MD (7) · Judith Karp (7) · Michele Baccarani, MD (7)
PMID 32499241, PMID 24383844, PMID 25527568, PMID 35235189, PMID 23524640, PMID 23620574, PMID 28835440, PMID 30885996, PMID 23065508, PMID 25361995, PMID 31375516, PMID 35982483, PMID 36184192, PMID 37042865, PMID 39516087, PMID 20965785, PMID 22825216, PMID 34699069, PMID 37553873, PMID 40535755, PMID 41758981, PMID 41958363, PMID 42316774, PMID 16775234, PMID 17151364, PMID 17715389, PMID 18997171, PMID 19797518, PMID 21403127, PMID 21447834, PMID 21450900, PMID 21715313, PMID 22133778, PMID 22430088, PMID 22692507, PMID 23116602, PMID 23515925, PMID 23704092, PMID 23911705, PMID 24323036, PMID 24859364, PMID 24919837, PMID 26069290, PMID 26888022, PMID 27291777, PMID 28273028, PMID 28543980, PMID 28572163, PMID 28962635, PMID 29217781
P30CA015704 (43), P30CA006973 (30), P30CA033572 (22), P30CA043703 (20), 2023 (19), P01CA018029 (18), U01CA070095 (17), U10CA032102 (17), P01CA108671 (16), P30CA016672 (16), U10CA031946 (15), 2018 (12), P30CA072720 (11), 2017 (10), P30CA015083 (10)